Senzime has submitted application for cross-trading at OTCQX in the US
Senzime, an industry leader in algorithm-based patient monitoring solutions announces the submission of an application for cross-trading of the Senzime share on the OTCQX trading platform. Upon approval, Senzimes shares will in parallel to its current Nasdaq Main Market listing, be traded with a US ticker symbol and a share price in USD.
OTCQX is a trading platform in the United States operated by the OTC Markets Group, as an alternative to listing on Nasdaq New York and NYSE. Cross-trading on OTCQX helps satisfy an increasing interest from US investors and increase accessibility to the US capital market. Upon approval, Senzimes shares will be traded with a US ticker symbol and a share price in USD, during US market hours.
"Around 15 percent of the shares in Senzime are held by US investors, and the majority of our revenues are generated from the US market. As a result, we want to make it easier for US investors to trade in the Senzime share”, comments Philip Siberg, CEO of Senzime AB.